These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 26581250)
1. Hypertension: New study REVEALs no survival benefit of warfarin for IPAH. Huynh K Nat Rev Cardiol; 2016 Jan; 13(1):4. PubMed ID: 26581250 [No Abstract] [Full Text] [Related]
2. Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL). Preston IR; Roberts KE; Miller DP; Sen GP; Selej M; Benton WW; Hill NS; Farber HW Circulation; 2015 Dec; 132(25):2403-11. PubMed ID: 26510696 [TBL] [Abstract][Full Text] [Related]
4. Warfarin in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension. A Bayesian approach to evaluating treatment for uncommon disease. Johnson SR; Granton JT; Tomlinson GA; Grosbein HA; Le T; Lee P; Seary ME; Hawker GA; Feldman BM J Rheumatol; 2012 Feb; 39(2):276-85. PubMed ID: 22247353 [TBL] [Abstract][Full Text] [Related]
5. Effect of warfarin on survival in scleroderma-associated pulmonary arterial hypertension (SSc-PAH) and idiopathic PAH. Belief elicitation for Bayesian priors. Johnson SR; Granton JT; Tomlinson GA; Grosbein HA; Hawker GA; Feldman BM J Rheumatol; 2011 Mar; 38(3):462-9. PubMed ID: 21159827 [TBL] [Abstract][Full Text] [Related]
6. Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Olsson KM; Delcroix M; Ghofrani HA; Tiede H; Huscher D; Speich R; Grünig E; Staehler G; Rosenkranz S; Halank M; Held M; Lange TJ; Behr J; Klose H; Claussen M; Ewert R; Opitz CF; Vizza CD; Scelsi L; Vonk-Noordegraaf A; Kaemmerer H; Gibbs JS; Coghlan G; Pepke-Zaba J; Schulz U; Gorenflo M; Pittrow D; Hoeper MM Circulation; 2014 Jan; 129(1):57-65. PubMed ID: 24081973 [TBL] [Abstract][Full Text] [Related]
7. Anticoagulation in pulmonary arterial hypertension: a qualitative systematic review. Johnson SR; Mehta S; Granton JT Eur Respir J; 2006 Nov; 28(5):999-1004. PubMed ID: 17074918 [TBL] [Abstract][Full Text] [Related]
8. Effect of warfarin on survival in patients with concomitant left ventricular systolic dysfunction and pulmonary hypertension: a population cohort study. Goudie A; Elder D; Deshmukh H; Szwejkowski BR; Lang CC; George J Eur J Heart Fail; 2015 Jan; 17(1):90-7. PubMed ID: 25427720 [TBL] [Abstract][Full Text] [Related]
9. Unilateral absence of a left pulmonary artery: successful therapeutic response to a combination of bosentan and warfarin. Ghanbari H; Feldman D; David S; Saba S Circ Cardiovasc Imaging; 2009 Nov; 2(6):e46-8. PubMed ID: 19920035 [No Abstract] [Full Text] [Related]
10. A descriptive evaluation of warfarin use in patients with pulmonary arterial hypertension. Irwin AN; Johnson SG; Joline BR; Delate T; Witt DM Thromb Res; 2014 May; 133(5):790-4. PubMed ID: 24642007 [TBL] [Abstract][Full Text] [Related]
11. First data from Latvian chronic thromboembolic pulmonary hypertension registry. Skride A; Sablinskis K; Rudzitis A; Lesina K; Lejnieks A Eur J Intern Med; 2016 Jul; 32():e23-4. PubMed ID: 26851983 [No Abstract] [Full Text] [Related]
12. Thrombotic arteriopathy and anticoagulation in pulmonary hypertension. Johnson SR; Granton JT; Mehta S Chest; 2006 Aug; 130(2):545-52. PubMed ID: 16899857 [TBL] [Abstract][Full Text] [Related]
14. Can anticoagulants improve the survival rate for patients with idiopathic pulmonary arterial hypertension? A systematic review and meta-analysis. Wang P; Hu L; Yin Y; Yan D; Zheng H; Zhang J; Li Y Thromb Res; 2020 Dec; 196():251-256. PubMed ID: 32920295 [TBL] [Abstract][Full Text] [Related]
15. Impact on survival of warfarin in patients with pulmonary arterial hypertension receiving subcutaneous treprostinil. Ascha M; Zhou X; Rao Y; Minai OA; Tonelli AR Cardiovasc Ther; 2017 Oct; 35(5):. PubMed ID: 28643420 [TBL] [Abstract][Full Text] [Related]
17. Case 1: chronic thromboembolic pulmonary hypertension (CTEPH). Murphy DT; Murphy DM; Murray JG; Gaine SP Ir Med J; 2013 May; 106(5):146-7. PubMed ID: 23914576 [No Abstract] [Full Text] [Related]
18. Successful treatment with immunosuppression, anticoagulation and vasodilator therapy of pulmonary hypertension in SLE associated with secondary antiphospholipid syndrome. Tam LS; Li EK Lupus; 1998; 7(7):495-7. PubMed ID: 9796854 [TBL] [Abstract][Full Text] [Related]
19. Control of long-term anticoagulant therapy. Lawson DH; McDonald GA Scott Med J; 1967 Apr; 12(4):163-5. PubMed ID: 6034271 [No Abstract] [Full Text] [Related]
20. Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension. Archer SL; Michelakis ED N Engl J Med; 2009 Nov; 361(19):1864-71. PubMed ID: 19890129 [No Abstract] [Full Text] [Related] [Next] [New Search]